2000-090987/08 A96 B05 (B07) **SAWA 1998.05.07**
SAWAI SEIYAKU KK *JP 11322584-A
1998.05.07 1998-124860(+1998JP-124860) *(1999.11.24)* A61K 9/16, 9/22, 31/195, 47/38

Bezafibrate sustained release formulation used as antilipemic - consists of bezafibrate and hydroxy propyl cellulose
C2000-026171

A(3-A4A1, 12-V1) B(4-C2A2, 10-B2E, 12-M10A, 14-F6) .4

NOVELTY

The bezafibrate formulation contains bezafibrate and 2 weight percent aqueous solution of hydroxy-propyl cellulose. The formulation has viscosity of 1-5 centipoise.

USE

As antilipemic.

ADVANTAGE

The formulation has excellent-self sustaining effect and is manufactured easily. Sticking of tablets during tabletting process is prevented and the formulation administered is in compact form.

POLYMERS

Preferred Substances: The bezafibrate formulation preferably contains 0.01-0.5 weight parts (wt. pts) of hydroxy-propyl cellulose (HPC) for 1 wt. pt of bezafibrate. The formulation additionally contains polyvinyl alcohol and hydroxy-propyl methyl cellulose.

EXAMPLE

(In wt. pts) Bezafibrate (80), HPC (13), crystal cellulose (5), silicic acid anhydride (1) and magnesium stearate (1) were mixed, granulated and dried for 2 hours at 80 °C. Magnesium stearate (1) and silicic acid anhydride (1) were added and compression molding was performed so that the tablet weight was set to 250 mg. Sticking was not observed during tabletting.
(4pp3143DwgNo.0/0)

JP 11322584-A